Eli Lilly | LLY - Les Charges D'Exploitation

Prix De L'Action
886.19
Variation Quotidienne
2.23 0.25%
Mensuellement
-0.05%
Annuel
1.01%
Q2 Prévisions
865.04




Les Charges D'Exploitation Changement Date
AbbVie USD 10.81B 13.45B 2025-12
Abbott USD 9.31B 104M 2026-03
ALKERMES USD 326.44M 1.41B 2025-12
Amgen USD 5.9B 773M 2025-12
AstraZeneca USD 12.53B 4.16B 2025-12
Baxter International USD 3.19B 554.4M 2025-12
Biogen USD 1.88B 81.4M 2025-09
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Coherus Biosciences USD 51.83M 2.48M 2025-12
Drreddys Laboratories INR 72.94B 4.33B 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 7.18B 1.42B 2025-12
Glaxosmithkline GBP 9.17B 1.4B 2025-12
J&J USD 17.44B 1.53B 2026-03
Medtronic USD 7.28B 16M 2025-12
Merck USD 10.16B 558M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Novartis USD 9.8B 61M 2025-12
Novartis USD 9.8B 23M 2025-12
Novo Nordisk DKK 46.76B 3.99B 2025-12
Perrigo USD 1.03B 75.3M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
Phibro Animal Health USD 332.36M 20.68M 2025-12
Prestige Brands USD 200.95M 6.51M 2025-12
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Roche Holding CHF 21.01B 10.84B 2025-12
Sanofi EUR 9.31B 1.2B 2026-03
Sanofi EUR 10.71B 1.32B 2025-12
United Therapeutics USD 804.8M 5.79B 2025-12
Zoetis USD 1.55B 3.85B 2025-12